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What’s new? 
 There is a dose–response between how often sitting is interrupted and basal glucose 
control. 
 Frequent interruptions of prolonged sitting with short light-intensity walking breaks every 
15 min reduce fasting glucose, magnitude of the dawn phenomenon, duration of the dawn 
phenomenon and night-time glycaemic variability. 
 Interrupting sedentary time every 15 min with short light-intensity walking breaks could be a 
simple therapy to improve basal glucose control. 
 
Abstract 
Aim To explore the dose–response between frequency of interruption of sedentary time and basal 
glucose (fasting glucose, the dawn phenomenon and night-time glucose) in Type 2 diabetes. 
 
Methods In a randomized three-treatment, two-period balanced incomplete block trial, 12 people 
with Type 2 diabetes (age, 60.0 ± 3.2 years; BMI, 30.2 ± 1.4 kg/m2) completed two of three 
conditions: sitting for 7 h interrupted every 60 min (Condition 1), 30 min (Condition 2), and 15 min 
(Condition 3) by 3-min light-intensity walking breaks. The activPAL3 and FreeStyle Libre were used to 
assess physical activity/sedentary behaviour and continuous glucose profile. Standardized meals 
were provided, and changes in basal glucose of the nights and early mornings before and after 
treatment conditions were calculated (mean ± SE). 
 
Results After treatment conditions, fasting glucose and duration of the dawn phenomenon were 
lower for Condition 3 (−1.0 ± 0.2 mmol/l, P < 0.02; −3.1 ± 1.3 h, P = 0.004) compared with Condition 
1 (−0.1 ± 0.2 mmol/l; 1.9 ± 1.2 h). The magnitude of the dawn phenomenon was reduced in 
Condition 3 (−0.6 ± 0.4 mmol/l, P = 0.041) compared with Condition 2 (0.6 ± 0.3 mmol/l). Night-time 
glycaemic variability (coefficient of variation) was reduced in Condition 3 (−9.7 ± 3.9%) relative to 
Condition 2 (6.1 ± 4.8%, P < 0.03) and Condition 1 (2.5 ± 1.8%, P = 0.02). There was no change in 
night-time mean glucose. 
 
Conclusions Frequent interruptions of prolonged sitting with 3 min of light-intensity walking breaks 
every 15 min improves fasting glucose, the dawn phenomenon and night-time glycaemic variability, 
and this might be a simple therapeutic intervention to improve glucose control. 
 
Clinicaltrials.gov Identifier: NCT02738996 
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<H1>Introduction 
Basal hyperglycaemia, including high fasting glucose, the dawn phenomenon and night-time glucose, 
could be indicative of insulin resistance and pancreatic β-cell deficiency, which are two important 
underlying mechanisms in Type 2 diabetes [1–3]. Basal hyperglycaemia influences daily glucose and 
HbA1c control [2,4]. It makes a greater contribution to overall hyperglycaemia in people with HbA1c 
> 68 mmol/mol (8.4%), whereas postprandial glucose is a main contributor in people with HbA1c 
< 56 mmol/mol (7.3%) [5]. Consequently, basal hyperglycaemia can lead to vascular complications 
[6], so good basal glucose control is important. However, high fasting glucose and the dawn 
phenomenon, defined as a spontaneous elevation of glucose from nocturnal (starting at midnight) 
nadir glucose to pre-breakfast glucose, have been reported in people with Type 2 diabetes, even 
with combination therapy of oral anti-diabetes agents [2,7,8]. This suggests that medications might 
not be enough to address basal hyperglycaemia, and adjunct lifestyle interventions are needed. 
There is evidence that sedentary time is associated with high fasting glucose, insulin resistance and 
metabolic risk profile [9–11]. By contrast, breaks in sedentary time have a beneficial effect on 
metabolic risk profile and postprandial glucose, and this beneficial effect might extend to basal 
glucose control [12]. A break in sedentary time is defined as a short period of standing or walking 
between two periods of sitting [13]. The reduction in postprandial glucose and insulin resistance 
with light-intensity walking breaks is well established in healthy adults and those with Type 2 
diabetes in an experimental laboratory setting [14]. However, experimental evidence to inform the 
beneficial effect of light-intensity walking breaks in sedentary time on fasting glucose, the dawn 
phenomenon and night-time glucose is limited. One experimental study showed a reduction in 
night-time glucose with 3-min light-intensity walking breaks every 30 min compared with 
uninterrupted sitting (7 h) [15]. However, in real life people very rarely sit all day but rather naturally 
break sitting on an irregular basis [16], and there is limited consensus on how frequently sitting 
should be interrupted. It is therefore important to find out if more frequent breaks have a beneficial 
effect. In other words, the dose–response relationship between frequency of breaks and basal 
glucose needs to be explored to inform potential therapeutic intervention based on breaking 
sedentary time. This study aimed to compare the effect of light-intensity walking breaks every 
60 min of sitting with light-intensity walking breaks every 30 min and 15 min on fasting glucose, the 
dawn phenomenon and night-time glucose. 
 
<H1>Methods 
<H2>Study design 
This three-treatment, two-period balanced incomplete block trial was approved by the Research 
Ethics Committees of Glasgow Caledonian University and University of Strathclyde. This study design 
has been used in pharmaceutical trials, and it reduces trial duration, participant burden, attrition 
rate and intra-subject effect, thus increasing the reliability of data and precision of study [17]. The 
study is registered as a clinical trial (Clinicaltrials.gov Identifier: NCT02738996). It was conducted in 
accordance with the Declaration of Helsinki. Eligible participants provided signed, written informed 
consent. 
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Participants completed two of the following three treatment conditions: sitting interrupted by 3 min 
light-intensity walking breaks every 60 min (Condition 1), 30 min (Condition 2) or 15 min (Condition 
3). 
<H2>Participants and recruitment 
Participants were recruited between January and June 2017 from diabetes support groups in 
Glasgow. Eligibility criteria included self-reported Type 2 diabetes, age ≥ 35 years and BMI 
≥ 25 kg/m2. Exclusion criteria were insulin therapy, pregnancy, liver and renal diseases, cancer, 
alcohol and substance abuse, mobility issues and diabetes-related complications such as foot ulcer, 
foot deformity, peripheral neuropathy and peripheral arterial diseases. 
 
<H2>Randomization 
Until the first treatment condition day, participants were blinded to trial condition order. The order 
was assigned using block randomization sequence produced by SPSS. 
 
<H2>Experimental protocol 
The total duration of the experimental protocol was 15 days: 4 days of pre-experimental monitoring, 
1 day of first treatment condition, 5 days of wash-out period, 1 day of second treatment condition 
and 4 days of post-experimental monitoring. Participants resumed their habitual diet and physical 
activity during the pre-experimental monitoring, wash-out and post-experimental monitoring 
periods, and refrained from alcohol, smoking and moderate to vigorous physical activity (MVPA) 
throughout the study. To ensure compliance with protocol, they were reminded at each visit. 
 
<H2>Pre-experimental monitoring period (visit 1) 
Participants visited the university laboratory at Glasgow Caledonian University or University of 
Strathclyde. A researcher recorded participants’ demographic information and medication history. 
Participants were fitted with a continuous glucose monitoring (CGM, Abbott FreeStyle Libre) and 
activPAL3 activity monitor (PAL Technologies, Glasgow, UK). They were provided with a FreeStyle 
Libre reader to scan glucose every 8 h, a sleep diary to record bedtime and waking time, and a 24-h 
dietary recall form to record medication and dietary intake during study period. Participants then 
completed their normal daily living behaviour for 4 days. 
 
<H2>First treatment condition (visit 2) 
After an overnight fast (starting at 22:00 h), participants reported to the laboratory at 08:00 h. 
Participants remained seated for 1 h to achieve a steady state. The internet, a personal computer 
and books were provided for entertainment. A standardized breakfast, consisting of 50–53.7 g 
carbohydrate, 9.1–12.6 g fat, 14.7–22.4 g protein and 1.4–1.7 MJ energy, was consumed at 09:00 h. 
One of the following treatment conditions commenced after breakfast according to the 
randomization order: 
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1. Condition 1. Participants performed 3 min of light-intensity walking on level ground every 
60 min at a pace of 10 m in 11 s (3.2 km/h), and timing and supervision were done by the 
researcher to ensure full adherence to the treatment condition as per protocol. Participants 
then sat for 60 min, and this was repeated until the end of treatment condition (16:00 h). 
There were six bouts (18 min) of walking. 
2. Condition 2. The procedure was identical to Condition 1, but participants walked for 3 min 
every 30 min of sitting. There were 12 bouts (36 min) of walking. 
3. Condition 3. The procedure was the same as above two conditions except that 3 min of 
walking was introduced every 15 min of sitting. Participants performed 23 bouts (69 min) of 
walking. 
Participants consumed a standardized lunch with 75 g carbohydrate, 14.5 g fat, 28 g protein and 
2.2 MJ energy at 12:36 h. Participants were also provided with a ready-meal dinner, consisting of 
50.1–55.6 g carbohydrate, 7.3–12.3 g fat, 20.1–30.1 g protein and 1.4–1.8 MJ energy, and a snack, 
consisting of 10–13.1 g carbohydrate, 0.3–0.6 g fat, 0.3–2.6 g protein and 0.2–0.3 MJ energy, to 
consume at home after treatment condition. Dinner was consumed between 18:00 h and 21:00 h, 
and the snack between 16:30 h and 22:00 h. On treatment condition days, participants were only 
allowed to have meals they were provided with. Participants refrained from caffeine in addition to 
alcohol, smoking and MVPA. 
 
<H2>Wash-out period 
A 5-days of wash-out period was introduced between two treatment conditions to avoid the 
potential carryover effect. 
 
<H2>Second treatment condition (visit 3) 
Procedures, diet and meal time were identical to the first treatment condition except that 
participants performed another of the three treatment conditions, which was not performed on the 
first treatment condition day. 
 
<H2>Post-experimental monitoring period (visit 4) 
After 4 days of post-experimental monitoring, participants visited the laboratory to remove the CGM 
and activPAL3. This was the end of the trial period. 
 
<H2>Physical activity and sedentary behaviour monitoring 
Participants wore the activPAL3 using hypoallergic dressing and waterproof plastic tubing. This is a 
validated device that accurately records the start and duration of physical activity, and sedentary 
bouts and walking cadence for 2 weeks [18]. This device estimates energy expenditure (metabolic 
equivalents, MET). activPAL3TM software (version 7.2.32) was used to download the data. 
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activPAL data for 3 days before each treatment condition were used to calculate baseline daily 
sedentary time, standing time and walking time after sleeping time was excluded using the sleep 
diary and activPAL file. Baseline energy expenditure during 3 days before the treatment condition 
and energy expenditure on treatment condition day were computed using the 24-h activPAL data. 
 
<H2>Continuous glucose monitoring 
Participants wore the CGM providing interstitial glucose records every 15 min for 2 weeks. The 
sensor was inserted into the subcutaneous tissue on the back of upper arm. The interstitial glucose 
value recorded using this well-tolerated consumer grade device is as accurate as the capillary blood 
glucose [19]. The accuracy is not influenced by type of diabetes, HbA1c, age and BMI [19]. The reader 
and FreeStyle Libre software (version 1.0) were respectively used to retrieve the data wirelessly 
every 8 h and to download the glucose data. 
 
Glucose outcome measures were changes in fasting glucose, magnitude and duration of the dawn 
phenomenon, night-time mean glucose and night-time glycaemic variability [coefficient of variation 
(CV%) = (SD/mean) × 100] of the nights and early mornings before and after treatment conditions. 
Changes in glucose variables were calculated by subtracting glucose values before treatment 
conditions from glucose values after treatment conditions. The CGM glucose value just before the 
start of breakfast was defined as fasting glucose (pre-breakfast glucose) [20]. The dawn 
phenomenon was calculated by subtracting nocturnal (starting at midnight) nadir glucose from pre-
breakfast glucose [8]. The time interval between nocturnal nadir glucose and pre-breakfast glucose 
was defined as the duration of the dawn phenomenon [8]. If all nocturnal glucose values were 
greater than the pre-breakfast glucose value, the dawn phenomenon and duration of the dawn 
phenomenon were recorded as zero [8]. The period between bedtime and waking time reported in 
the sleep diary was defined as night-time. Night-time mean glucose and glycaemic variability (CV%) 
were calculated using glucose values during this period. 
 
<H2>Statistical analyses 
Sample size calculations were based on a previous study [21]. Allowing for a statistical power of 80%, 
a 0.05 probability level and a correlation of 0.5 between repeated measures, we estimated that 12 
participants would be needed to detect a 24% change in glucose based on the effect size observed in 
this previous study [21]. There were no inclusion or exclusion criteria regarding missing glucose 
values. Across all treatment conditions, 3.5% of night-time glucose values (54 of 1527 glucose points) 
were missing, and within-individual mean substitution was applied. Within-individual mean 
substitution might underestimate standard errors (SE), however, this method has been shown to be 
effective and accurate to deal with ≤ 10% of missing data [22]. 
 
Multilevel mixed-effects linear regression allowing repeated measures for the same individuals was 
used to assess changes in glucose variables between conditions. Model 1 was adjusted for age 
(years), sex, BMI (kg/m2), carbohydrate intake (g/day) and energy expenditure (MET × h/day) on 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
treatment condition day, and Model 2 was additionally adjusted for anti-diabetes medication dose 
(mg/day), sedentary time (h/day) and walking time (h/day) on treatment condition day. All variables 
were added as continuous variables except for gender. Differences in baseline participant 
characteristics were assessed with multilevel mixed-effects linear regression. To locate differences 
between conditions, pairwise comparisons were performed using post hoc Fisher LSD tests. 
Statistical analyses were conducted using IBM SPSS Statistics software (version 24.0). Data are 
expressed as mean ± SE unless otherwise indicated, and P ≤ 0.05 was considered statistically 
significant. No adjustment was applied for multiple comparisons. 
 
<H1>Results 
Twelve participants (eight men, four women; mean duration of diabetes, 5.2 ± 0.8 years; mean age, 
60.0 ± 3.2 years; mean BMI, 30.2 ± 1.4 kg/m2) were randomized and completed trial conditions. 
Baseline participant characteristics before treatment conditions are displayed in Table 1, and no 
significant differences between conditions were observed. 
Table 2 shows the changes in glucose variables in three treatment conditions. Fasting glucose was 
significantly lowered in Condition 3 (−1.0 ± 0.2 mmol/l, P < 0.02), but not after Condition 2 
(−0.6 ± 0.2 mmol/l, P = 0.12) compared with Condition 1 (−0.1 ± 0.2 mmol/l). Moreover, the duration 
of the dawn phenomenon was significantly reduced in Condition 3 (−3.1 ± 1.3 h, P = 0.004), but not 
in Condition 2 (−0.1 ± 1.4 h, P = 0.37) in comparison with Condition 1 (1.9 ± 1.2 h). Compared with 
Condition 2 (0.6 ± 0.3 mmol/l), there was significant reduction in the magnitude of the dawn 
phenomenon after Condition 3 (−0.6 ± 0.4 mmol/l, P = 0.041). In addition, Condition 3 (−9.7 ± 3.9%) 
significantly reduced night-time glycaemic variability (CV%) compared with Condition 2 (6.1 ± 4.8%, 
P<0.03) and Condition 1 (2.5 ± 1.8%, P=0.02). 
A reduction in fasting glucose and the duration of the dawn phenomenon in Condition 3 (−1.0 ± 0.2 
mmol/l, P < 0.02; −3.0 ± 2.1 h, P < 0.03) relative to Condition 1 (−0.1 ± 0.2 mmol/l; 1.9 ± 1.6 h) was 
observed, independent of medication, sedentary time and walking time (Model 2). Moreover, there 
was a consistent reduction in the magnitude of the dawn phenomenon and night-time glycaemic 
variability (CV%) in Condition 3 (−0.6 ± 0.4 mmol/l, P < 0.01; −6.1 ± 3.8%, P < 0.04) compared with 
Condition 2 (0.8 ± 0.3 mmol/l; 5.2 ± 3.2%). No difference in night-time mean glucose was observed in 
both Model 1 and Model 2. 
 
<H1>Discussion 
The main finding of this study is that interrupting prolonged sitting frequently (at least every 15 min 
) improves basal glucose control in Type 2 diabetes. Lower fasting glucose, the magnitude and 
duration of the dawn phenomenon, and night-time glycaemic variability (CV%) were observed if the 
previous day sedentary time was interrupted more frequently. 
In this study, no change in fasting glucose after Condition 2 is in agreement with the previous finding 
in overweight and obese adults with Type 2 diabetes with standing and walking breaks every 30 min 
[23]. To date, only one experimental study has shown a reduction in night-time mean glucose with 3-
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min walking breaks every 30 min in comparison with uninterrupted sitting (7 h) [15], but our study 
did not observe the difference in night-time mean glucose between treatment conditions. The 
lowering of night-time glycaemic variability (CV%) after more frequent breaks (Condition 3) is similar 
to the reduction in 22 h glycaemic variability reported previously [15]. The lower glycaemic 
variability and basal glucose with frequent walking breaks might contribute to reducing risks of 
vascular complications [6,24]. 
Basal glucose control is one of the main therapeutic goals of diabetes management. However, most 
anti-diabetes agents, such as prandial glucose regulators, -glucosidase inhibitors and incretins, are 
designed to reduce postprandial glucose, and increasing the sulphonylurea dose is not ideal to 
control basal glucose because of the risk of hypoglycaemia [2]. Among oral anti-diabetes agents, 
metformin is effective in reducing fasting glucose and insulin resistance. However; basal glucose is 
not adequately controlled by metformin or a combination of oral anti-diabetes agents [2,7,8]. In 
addition to anti-diabetes agents, at least 150 min of MVPA per week is recommended to improve 
glucose control and pancreatic β-cell function, and to reduce insulin resistance [25]. However, 
adherence to exercise is often suboptimal in people with Type 2 diabetes. 
This study found that light-intensity walking breaks improved basal glucose. The mechanism for this 
is unclear. However, frequent interruption of sedentary time every 15 min could be considered in 
addition to the current treatment regimen. A feasibility study conducted in overweight and obese 
adults discovered that breaks in sedentary time (3-min break every 30 min vs. 6-min break every 
60 min vs. 12-min break every 120 min) reduce sedentary time and improve physical activity, with 
greater compliance with more frequent breaks [26]. But, the feasibility and clinical relevance of 
walking breaks in free-living conditions in Type 2 diabetes should be tested in future studies. 
This study has a number of strengths. First, the reference condition (Condition 1) and light-intensity 
walking (3.2 km/h) on level ground were relatively closer to habitual sedentary and activity patterns 
observed in Type 2 diabetes [16,27]. Second, this is the first study to compare the effects of different 
frequencies of walking breaks on basal glucose, especially the dawn phenomenon, although 
postprandial metabolic responses to different frequencies of standing breaks have been investigated 
previously [28]. Third, analyses were adjusted for different confounding variables, which might 
influence glucose homeostasis. Finally, the activPAL3 and CGM allowed relatively long duration of 
sedentary behaviour/physical activity and interstitial glucose monitoring. 
This study also has some limitations. First, the study had a small sample size and might be 
underpowered to detect some of the changes in glucose variables. The small sample size (n = 10) 
and controlled laboratory settings had been used in previous studies [28,29]. We therefore suggest 
future definitive randomized controlled trials with larger sample size in free-living settings. Second, 
usual glucose control, such as fasting glucose and HbA1c levels, were not assessed to consider as 
inclusion or exclusion criteria for the selection of participants. Regular light-intensity walking breaks 
in sedentary time could have greater beneficial effects on glucose control in individuals with higher 
baseline fasting glucose and insulin resistance [30]. The dose–response of frequency of breaks might 
be more prominent in these individuals, and should be evaluated in future studies. Third, an acute 
effect rather than longer-term exposure of light-intensity walking breaks was investigated in this 
study. Fourth, the dinner before treatment conditions was not standardized. Fifth, standardized 
meals provided were not adjusted for the body weight and daily energy requirements of each 
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participant. Sixth, the difference in sedentary time, physical activity time, energy expenditure and 
timing of activity breaks in relation to meals could influence the effect of breaks. Future studies 
should compare different frequencies of breaks when these factors are matched. Finally, the dose–
response of breaks on insulin resistance could not be assessed directly due to lack of insulin 
measurement. Nonetheless, lower fasting glucose and the dawn phenomenon in response to 
Condition 3 could reflect improved insulin sensitivity [1–3]. Observational and experimental studies 
have already reported that breaks in sedentary time improve insulin homeostasis [10,14]. 
In conclusion, this study demonstrates the dose–response of frequency of light-intensity walking 
breaks on basal glucose. The introduction of short frequent breaks in sedentary time could be an 
effective approach to improve fasting glucose, the dawn phenomenon and night-time glycaemic 
variability. Longer-term exposure to light-intensity walking breaks every 15 min of sitting added to 
current treatment regimen might produce sustainable clinical effect in Type 2 diabetes, and this 
should be explored in long-term studies. 
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Table 1 Baseline participant characteristics before treatment conditions 
Data are means ± SE or n (%). 
CV, coefficient of variation. 
*Sedentary and activity time during three days before treatment conditions. 
†Energy expenditure during three days before treatment conditions. 
‡Basal glucose of the nights and early mornings before treatment conditions. 
There were no significant differences in age, BMI, duration of diabetes, systolic blood pressure, diastolic blood 
pressure, sedentary and activity time, energy expenditure and basal glucose between treatment conditions. 
 
  
Participant characteristics Overall Condition 1 Condition 2 Condition 3 
No. of participants (n) 12 8 8 8 
Male : female (n) 8 : 4 7 : 1 5 : 3 5 : 3 
Age (years) 60.0 ± 3.2 60.3 ± 4.1 60.4 ± 4.2 59.5 ± 3.8 
BMI (kg/m2) 30.2 ± 1.4 29.9 ± 1.8 30.5 ± 1.8 30.4 ± 1.8 
Duration of diabetes (years) 5.2 ± 0.8 5.4 ± 1.0 4.9 ± 1.1 5.2 ± 1.1 
Systolic blood pressure (mmHg) 139.6 ± 3.1 139.1 ± 2.9 140.8 ± 2.9 138.9 ± 2.9 
Diastolic blood pressure (mmHg) 80.9 ± 1.9 81.3 ± 2.3 81.2 ± 2.3 80.2 ± 2.2 
Smoking status, n (%)     
 Non-smoker 11 (91.7) 7 (87.5) 8 (100) 7 (87.5) 
 Smoker 1 (8.3) 1 (12.5) 0 (0.0) 1 (12.5) 
Medications, n (%)     
 Metformin 7 (58.3) 5 (62.5) 5 (62.5) 4 (50.0) 
 Metformin + Gliclazide 4 (33.3) 2 (25.0) 3 (37.5) 3 (37.5) 
 Statin 5 (41.7) 3 (37.5) 3 (37.5) 4 (50.0) 
 Calcium channel blocker 2 (16.7) 2 (25.0) 1 (12.5) 1 (12.5) 
 Angiotensin converting enzyme inhibitor 2 (16.7) 2 (25.0) 2 (25.0) 0 (0.0) 
 Angiotensin receptor blocker 2 (16.7) 1 (12.5) 1 (12.5) 2 (25.0) 
 β blocker 1 (8.3) 1 (12.5) 1 (12.5) 0 (0.0) 
Anti-diabetes medication dose     
 Metformin (mg/day)  1227.3 ± 152.4 1214.3 ± 170.9 1187.5 ± 159.9 1285.7 ± 147.1 
 Gliclazide (mg/day) 80.0 ± 0.0 80.0 ± 0.0 80.0 ± 0.0 80.0 ± 0.0 
Sedentary and activity time (h/day)*     
 Sedentary time 10.2 ± 0.5 10.3 ± 0.7 10.2 ± 0.6 10.2 ± 0.6 
 Standing time 3.8 ± 0.4 3.6 ± 0.4 4.1 ± 0.4 3.7 ± 0.4 
 Walking time 1.5 ± 0.2 1.6 ± 0.2 1.5 ± 0.3 1.6 ± 0.2 
Energy expenditure (MET × h/day)† 33.4 ± 0.3 33.6 ± 0.3 33.3 ± 0.3 33.4 ± 0.3 
Basal glucose‡     
 Fasting glucose (mmol/l) 6.8 ± 0.4 6.2 ± 0.5 6.7 ± 0.5 7.4 ± 0.4 
 The dawn phenomenon (mmol/l) 1.7 ± 0.2 1.5 ± 0.3 1.5 ± 0.3 1.9 ± 0.3 
 Duration of the dawn phenomenon (h) 5.6 ± 0.8 5.3 ± 0.9 5.9 ± 0.9 5.7 ± 0.9 
 Night-time mean glucose (mmol/l) 6.2 ± 0.6 6.1 ± 0.8 6.2 ± 0.8 6.5 ± 0.8 
 Night-time glycaemic variability (CV%) 12.9 ± 3.2 14.4 ± 5.7 9.1 ± 1.5 12.8 ± 2.1 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 2 Change in glucose variables  
Data are marginal means ± SE. 
Model 1 was adjusted for age, sex, BMI, carbohydrate intake and energy expenditure. 
Model 2 was additionally adjusted for anti-diabetes medication dose, sedentary time and walking time. 
*Significantly different compared with Condition 3 (P ˂ 0.05). 
†CV, coefficient of variation. 
 
 
 
  
 
Glucose Condition 1 
(n = 8) 
Condition 2 
(n = 8) 
Condition 3 
(n = 8) 
Model 1    
 Fasting glucose (mmol/l) −0.1 ± 0.2* −0.6 ± 0.2 −1.0 ± 0.2 
 The dawn phenomenon (mmol/l) 0.3 ± 0.4 0.6 ± 0.3* −0.6 ± 0.4 
 Duration of the dawn phenomenon (h) 1.9 ± 1.2* −0.1 ± 1.4 −3.1 ± 1.3 
 Night-time mean glucose (mmol/l) −0.9 ± 0.4 −1.2 ± 0.3 −0.5 ± 0.4 
 Night-time glycaemic variability (CV%)† 2.5 ± 1.8* 6.1 ± 4.8* −9.7 ± 3.9 
Model 2    
 Fasting glucose (mmol/l) −0.1 ± 0.2* −0.6 ± 0.2 −1.0 ± 0.2 
 The dawn phenomenon (mmol/l) 0.2 ± 0.4 0.8 ± 0.3* −0.6 ± 0.4 
 Duration of the dawn phenomenon (h) 1.9 ± 1.6* −0.1 ± 0.4 −3.0 ± 2.1 
 Night-time mean glucose (mmol/l) −1.1 ± 0.3 −1.1 ± 0.3 −0.3 ± 0.4 
 Night-time glycaemic variability (CV%) −0.3 ± 3.5 5.2 ± 3.2* −6.1 ± 3.8 
